reviewEuropean Respiratory JournalMar 5, 2015BRONZE OA

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

Boehringer Ingelheim (Germany) · University Hospital of Basel · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease characterised by fibrosis of the lung parenchyma and loss of lung function. Although the pathogenic pathways involved in IPF have not been fully elucidated, IPF is believed to be caused by repetitive alveolar epithelial cell injury and dysregulated repair, in which there is uncontrolled proliferation of lung fibroblasts and differentiation of fibroblasts into myofibroblasts, which excessively deposit extracellular matrix (ECM) proteins in the interstitial space. A number of profibrotic mediators including platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and transforming growth factor-β are believed to play…

Citation impact

972
total citations
FWCI
39.77
Percentile
100%
References
95
Citations per year

Authors

7

Topics & keywords

Keywords
  • Nintedanib
  • Idiopathic pulmonary fibrosis
  • Medicine
  • Platelet-derived growth factor receptor
  • Hepatocyte growth factor
  • Fibrosis
  • Cancer research
  • Extracellular matrix
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding